Paratek Pharmaceuticals, Inc. (PRTK) financial statements (2020 and earlier)

Company profile

Business Address 75 PARK PLAZA
BOSTON, MA 02116
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:21529315212813196
Cash and cash equivalents10247355313196
Short-term investments11320311675  
Other undisclosed cash, cash equivalents, and short-term investments042(0)(0)  
Restricted cash and investments00012 
Receivables1006014
Inventory, net of allowances, customer advances and progress billings12     
Inventory12     
Other current assets     1
Other undisclosed current assets6(38)338 
Total current assets:243255160132142101
Noncurrent Assets
Operating lease, right-of-use asset3
Property, plant and equipment112110
Long-term investments and receivables 42    
Long-term investments 42    
Intangible assets, net (including goodwill)111226
Goodwill111111
Intangible assets, net (excluding goodwill)  0115
Restricted cash and investments300003
Other noncurrent assets00000 
Total noncurrent assets:8453449
TOTAL ASSETS:251300164136146110
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities211515834
Accounts payable424410
Accrued liabilities171311113
Employee-related liabilities   311
Debt     5
Other liabilities3     
Other undisclosed current liabilities 221217(6)
Total current liabilities:24181720214
Noncurrent Liabilities
Long-term debt and lease obligation263229593920 
Long-term debt, excluding current maturities261229593920 
Operating lease, liability2
Liabilities, other than long-term debt4655510
Deferred tax liabilities, net    2
Other liabilities465444
Business combination, contingent consideration, liability  0115
Other undisclosed noncurrent liabilities     1
Total noncurrent liabilities:26723564442411
Total liabilities:29125381644515
Stockholders' equity
Stockholders' equity attributable to parent(40)48827210195
Common stock000000
Additional paid in capital671630553452370293
Accumulated other comprehensive income (loss)0(0)(0)(0)  
Accumulated deficit(711)(582)(470)(380)(269)(198)
Total stockholders' equity:(40)48827210195
TOTAL LIABILITIES AND EQUITY:251300164136146110

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues1717130 4
Revenue, net130 4
Cost of revenue(3)    (2)
Gross profit:1317130 2
Operating expenses(129)(121)(98)(110)(74)(10)
Other undisclosed operating income 0104 
Operating loss:(116)(104)(85)(109)(70)(8)
Nonoperating income (expense)4311(0)(0)
Investment income, nonoperating4311(0)(0)
Interest and debt expense(16)(11)(5)(3)  
Loss from continuing operations before equity method investments, income taxes:(128)(112)(88)(112)(70)(8)
Other undisclosed loss from continuing operations before income taxes(0)     
Loss from continuing operations before income taxes:(128)(112)(88)(112)(70)(8)
Income tax expense(0)(1)(1)   
Net loss:(129)(112)(89)(112)(70)(8)
Other undisclosed net loss attributable to parent    (1)(10)
Net loss attributable to parent:(129)(112)(89)(112)(71)(18)
Preferred stock dividends and other adjustments     (2)
Net loss available to common stockholders, basic:(129)(112)(89)(112)(71)(20)
Convertible preferred dividends     (2)
Net loss available to common stockholders, diluted:(129)(112)(89)(112)(71)(22)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(129)(112)(89)(112)(70)(8)
Other comprehensive income (loss)00(0)(0)  
Comprehensive loss, net of tax, attributable to parent:(129)(112)(89)(112)(70)(8)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: